MGD stages: how severe is my meibomian gland dysfunction?

Meibomian gland dysfunction is usually described in four stages, set out by the 2011 International Workshop on MGD. They run from stage 1, where an optometrist can find signs on gland expression but you have no symptoms and no staining of the eye surface, to stage 4, where symptoms clearly limit what you do and dye staining reaches the centre of the cornea.

Staging is done by a clinician, not at home. It depends on expressing the glands, grading what comes out, and examining the lid margin and ocular surface at the slit lamp. You can tell roughly where your symptoms sit; you cannot see your own meibum quality or corneal staining.

The workshop's management report says that without generally accepted definitions for a staging system of clinical severity of MGD, it is problematic to propose a treatment plan based on disease stage, and offers the staging anyway to help clinicians build a logical approach. Treat it as a useful map, not a verdict.

Where the staging comes from

The MGD Workshop defined the condition as a chronic, diffuse abnormality of the meibomian glands, commonly characterised by terminal duct obstruction and by qualitative or quantitative changes in the secretion. Its management and treatment report then proposed two linked tables: a clinical summary of staging, and a treatment algorithm keyed to those stages.

Two caveats travel with them. The four-stage algorithm in the treatment report is not the same scheme as the one in the workshop's separate diagnosis report, which grades severity across six levels from 0 to 5 and adds a "subclinical" level for asymptomatic disease found only on expression. If two clinicians give you different numbers, that may be why. And the report notes that it is clinically difficult to separate the effects of MGD from those of aqueous-deficient dry eye on the ocular surface, with co-morbid conditions often present as well. If your optometrist hedges when you ask for a number, that is why.

What your optometrist is actually grading

Four things feed the stage.

• Symptoms. Discomfort, itching and light sensitivity, and specifically whether they limit your activities.
• Expressibility. Graded 0 to 3 across five glands by how many can be expressed: 0 if all of them, 1 if three or four, 2 if one or two, 3 if none.
• Meibum quality. Each of eight glands in the central third of the lower lid is scored 0 for clear, 1 for cloudy, 2 for cloudy with granular debris, and 3 for thick, toothpaste-like material, giving a total from 0 to 24.
• Lid margin and ocular surface. Plugging and visible vessels early on, gland dropout and lid margin displacement later, plus staining of the cornea and conjunctiva scored with dye.

Imaging of the glands themselves sits alongside this rather than inside the staging table. Our guide to what meibography shows covers how gland loss is assessed, and the signs of meibomian gland dysfunction covers what a clinician looks for before any of this begins.

The four stages, and what each tends to feel like

Stage 1. No symptoms of discomfort, itching or photophobia. Signs are present on gland expression, with minimally altered secretions, and there is no ocular surface staining. In practice it is found on a routine examination, not reported by the patient. The diagnosis report makes the same point from the other direction, noting that MGD goes through an asymptomatic, preclinical stage that may only be picked up by expressing the glands.

Stage 2. Minimal to mild symptoms. Scattered lid margin features, mildly altered secretions, and staining that is absent or limited. This is the stage most people arrive at the practice in: eyes that feel gritty by evening, tire quickly on screens, and blur intermittently until you blink.

Stage 3. Moderate symptoms with limitation of activities. More lid margin change, including plugging and visible vessels, moderately altered secretions, expressibility down to one or two glands of five, and mild to moderate conjunctival and peripheral corneal staining, often inferior. Reading and screen work get cut short, and drops become a several-times-a-day habit.

Stage 4. Marked symptoms with definite limitation of activities. Lid margin features increase further, with gland dropout and displacement, secretions are severely altered, no glands are expressible, staining extends to the centre of the cornea, and signs of inflammation appear, including at least moderate conjunctival redness.

Sitting across all four is what the workshop calls "plus" disease: specific conditions that can occur at any stage and need their own treatment, including exacerbated inflammatory surface disease, chalazion, trichiasis, phlyctenular keratitis, anterior blepharitis, and Demodex-related anterior blepharitis with cylindrical dandruff. You can have mild MGD and a significant plus condition at the same time, which is one reason the link between blepharitis and dry eye matters.

Questions to bring to your optometrist

Take the questions that produce the answer to your next appointment.

• How many of my lower lid glands gave liquid secretion when you expressed them?
• What did the meibum look like: clear, cloudy, granular, or like toothpaste?
• Is there staining on my cornea, and is it peripheral or central?
• Does meibography show gland loss, and roughly how much?
• Which stage does that put me at, and what does it change about my treatment?
• Is there a "plus" condition, such as blepharitis or Demodex, needing separate treatment?

One caution before you assume no symptoms means no disease. A review of nonobvious obstructive MGD described a form in which inflammation and other signs of pathology may be absent unless special examination techniques are used, argued that it may be the most common form of obstructive MGD, and judged it significantly underdiagnosed. Comfortable eyes and healthy glands are not the same thing.

How treatment escalates with stage

The workshop's algorithm has a clear shape: measures are added at each stage rather than swapped out.

At stage 1 the recommendation is information. Explain what MGD is, the potential impact of diet, how work and home environments affect tear evaporation, and the drying effect of some systemic medicines. Lid hygiene with warming and expression is listed as optional.

At stage 2, eyelid hygiene becomes a firm recommendation: eyelid warming for a minimum of four minutes, once or twice daily, followed by massage and expression of the secretions. Advice on ambient humidity, workstation set-up and dietary omega-3 sits alongside it, with artificial lubricants, topical azithromycin, an emollient lubricant or liposomal spray, and consideration of oral tetracycline derivatives all listed as options.

At stage 3, everything above continues, with oral tetracycline derivatives moving from optional to recommended, and lubricant ointment at bedtime and anti-inflammatory therapy available as indicated. At stage 4, everything above continues and anti-inflammatory therapy for dry eye becomes a recommendation rather than an option.

The practical message is that heat and lid hygiene enter at stage 2 and never leave. Prescription treatment is layered on top of a daily routine, not instead of it, which is why unblocking the glands at home matters as much at stage 4 as at stage 2. If you have an eye infection, have had eye surgery recently, have glaucoma, or notice any change in your vision, speak to your optometrist or ophthalmologist before starting heat therapy or continuing with it.

Because the warming step is the one most often done badly, it is the one worth making repeatable. The Meibocare E-Heated Eye Mask is designed to bring the eyelids to about 42 °C on the recommended setting and timer. It has three settings each with its own timer, 20 minutes on Low, 15 on Medium and 10 on High, and is notified to Medsafe on the New Zealand WAND database (240927-WAND-746QNT), a notification register rather than an approval. Our guide to warm compress temperature explains what any method must achieve.

Frequently asked questions

How many stages of meibomian gland dysfunction are there?

Four. The 2011 International Workshop on MGD set out stages 1 to 4, based on symptoms, how expressible the glands are, the quality of the meibum, lid margin changes and staining of the eye surface. A separate category called "plus" disease covers conditions such as chalazion or blepharitis that can occur at any stage and need their own treatment.

How do I know what stage of MGD I have?

Only an optometrist or ophthalmologist can tell you, because staging depends on expressing the glands and examining the lid margin and cornea at the slit lamp. You can describe your symptoms and whether they limit your activities, but meibum quality, gland expressibility and corneal staining all need an examination. Ask directly at your next appointment.

What does stage 2 MGD mean?

Minimal to mild symptoms of discomfort, itching or light sensitivity, with scattered lid margin changes, mildly altered secretions, and no more than limited staining of the eye surface. It is the stage at which the workshop's algorithm makes daily eyelid warming and expression a firm recommendation rather than an option, alongside advice on environment and diet.

Does MGD treatment change with the stage?

Yes, by addition rather than replacement. Stage 1 is largely information. Stage 2 adds daily eyelid warming, massage and expression, with lubricants and some topical options. Stage 3 adds oral tetracycline derivatives. Stage 4 adds anti-inflammatory therapy for dry eye. The daily lid routine started at stage 2 continues through every stage above it.

Educational information only, not medical advice. References: Nichols KK, et al. Invest Ophthalmol Vis Sci. 2011;52:1922–1929; Geerling G, et al. Invest Ophthalmol Vis Sci. 2011;52:2050–2064; Tomlinson A, et al. Invest Ophthalmol Vis Sci. 2011;52:2006–2049; Blackie CA, et al. Cornea. 2010;29:1333–1345.